Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5156-5160

  Croteau, David ^a   Letendre, Scott ^b   Best, Brookie M ^c,e   Ellis, Ronald J ^a   Breidinger, Sheila ^g   Clifford, David ^h   Collier, Ann ⁱ   Gelman, Benjamin ^j   Marra, Christina ⁱ   Mbeo, Gilbert ^k   McCutchan, Allen ^b   Morgello, Susan ^l   Simpson, David ^l   Way, Lauren ^d   Vaida, Florin ^f   Ueland, Susan ^b   Capparelli, Edmund ^c   Grant, Igor ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTI-HIV AGENTS; CHROMATOGRAPHY, LIQUID; FEMALE; HIV INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; TANDEM MASS SPECTROMETRY;

EID: 78649676916     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00507-10     Document Type: Article

References (26)

1. Adam, P., O. Sobek, L. Táborský, T. Hildebrand, O. Tutterová, and P. Zácek. 2003. CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin. Chim. Acta 334:107-110.
2. Best, B. M., S. L. Letendre, E. Brigid, D. B. Clifford, A. C. Collier, B. B. Gelman, J. C. McArthur, J. A. McCutchan, D. M. Simpson, R. Ellis, E. V. Capparelli, and I. Grant, for the CHARTER Group. 2009. Low atazanavir concentrations in cerebrospinal fluid. AIDS 23:83-87.
3. Capparelli, E., S. L. Letendre, R. J. Ellis, P. Patel, D. Holland, and J. A. McCutchan. 2005. Abacavir population pharmacokinetics in plasma and CSF. Antimicrob. Agents Chemother. 49:2504-2506.
4. Capparelli, E. V., D. Holland, C. Okamoto, B. Gragg, J. Durelle, J. Marquie-Beck, G. van den Brande, R. Ellis, and S. Letendre; the HNRC Group. 2005. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19:949-952.
5. Cysique, L. A., F. Vaida, S. Letendre, S. Gibson, M. Cherner, S. P. Woods, J. A. McCutchan, R. K. Heaton, and R. J. Ellis. 2009. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342-348.
6. Danovich, R., Y. Ke, H. Wan, B. Y. Nguyen, H. Teppler, W. Schleif, D. Hazuda, and M. Miller, for the BENCHMRK-1 and BENCHMRK-2 Study Groups. 2008. Raltegravir has similar in vitro antiviral potency, clinical efficacy, and resistance patterns in B subtype and non-B subtype HIV-1, abstr. TUAA0302, p. 305. Abstract book, vol. 1. XVII Int. AIDS Conf., Mexico City, Mexico, 3 to 8 August 2008. http://www.aids2008-abstracts.org/aids2008-book-vol1-web.pdf.
7. Ellis, R. J., M. E. Childers, J. D. Zimmerman, S. D. Frost, R. Deutsch, J. A. McCutchan, and the HIV Neurobehavioral Research Center Group. 2003. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy. J. Infect. Dis. 187:1818-1821.
8. Ellis, R. J., A. C. Gamst, E. Capparelli, S. A. Spector, K. Hsia, T. Wolfson, I. Abramson, I. Grant, and J. A. McCutchan. 2000. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54:927-936.
9. Ellis, R. J., K. Hsia, S. A. Spector, J. A. Nelson, R. K. Heaton, M. R. Wallace, I. Abramson, J. H. Atkinson, I. Grant, and J. A. McCutchan. 1997. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann. Neurol. 42:679-688.
10. Ellis, R. J., D. J. Moore, M. E. Childers, S. Letendre, J. A. McCutchan, T. Wolfson, S. A. Spector, K. Hsia, R. K. Heaton, and I. Grant. 2002. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch. Neurol. 59:923-928.
11. Haas, D. W., B. Johnson, J. Nicotera, V. L. Bailey, V. L. Harris, et al. 2003. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob. Agents Chemother. 47:2131-2137.
12. Letendre, S., R. Ellis, R. Heaton, I. Grant, and A. McCutchan. 2009. Neurocognitive complications of HIV and their management, abstr. 181. 16th Conf. Retrovir. Opportunistic Infect., Montreal, Quebec, Canada, 8 to 11 February 2009.
13. Letendre, S. L., E. V. Capparelli, R. J. Ellis, J. A. McCutchan, and the HIV Neurobehavioral Research Center Group. 2000. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 44:2173-2175.
14. Letendre, S. L., J. A. McCutchan, M. E. Childers, S. P. Woods, D. Lazzaretto, R. K. Heaton, I. Grant, and R. J. Ellis; HNRC Group. 2004. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann. Neurol. 56:416-423.
15. Letendre, S. L., G. van den Brande, A. Hermes, S. P. Woods, J. Durelle, J. M. Beck, J. A. McCutchan, C. Okamoto, R. J. Ellis, and the HIV Neurobehavioral Research Center Group. 2007. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin. Infect. Dis. 54:1511-1517.
16. Marra, C. M., Y. Zhao, D. B. Clifford, S. Letendre, S. Evans, K. Henry, R. J. Ellis, B. Rodriguez, R. W. Coombs, G. Schifitto, J. C. McArthur, K. Robertson, and the AIDS Clinical Trials Group 736 Study Team. 2009. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359-1366.
17. Masliah, E., R. K. Heaton, T. D. Marcotte, R. J. Ellis, C. A. Wiley, M. Mallory, C. L. Achim, J. A. McCutchan, J. A. Nelson, J. H. Atkinson, and I. Grant. 1997. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann. Neurol. 42:963-972.
18. McArthur, J. C., D. R. McClernon, M. F. Cronin, T. E. Nance-Sproson, A. J. Saah, M. St Clair, and E. R. Lanier. 1997. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann. Neurol. 42:689-698.
19. Merschman, S. A., P. T. Vallano, L. A. Wenning, B. K. Matuszewski, and E. J. Woolf. 2007. Determination of HIV integrase inhibitor, MK-0518 (raltegravir) in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 857:15-24.
20. Murray, J. M., S. Emery, A. D. Kelleher, M. Law, J. Chen, D. J. Hazuda, B. Y. Nguyen, H. Teppler, and D. A. Cooper. 2007. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21:2315-2321.
21. Simpson, D. M. 1999. Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Clin. Infect. Dis. 29:19-34.
22. Spudich, S., N. Lollo, T. Liegler, S. G. Deeks, and R. W. Price. 2006. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J. Infect. Dis. 194:1686-1696.
23. Tozzi, V., P. Balestra, M. F. Salvatori, C. Vlassi, G. Liuzzi, M. L. Giancola, M. Giulianelli, P. Narciso, and A. Antinori. 2009. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52:56-63.
24. Wenning, L. A., A. S. Petry, J. T. Kost, B. Jin, S. A. Breidinger, I. DeLepeleire, E. J. Carlini, S. Young, T. Rushmore, F. Wagner, N. M. Lunde, F. Bieberdorf, H. Greenberg, J. A. Stone, J. A. Wagner, and M. Iwamoto. 2009. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 85:623-627.
25. Wiley, C., R. Schrier, J. Nelson, P. W. Lampert, and M. B. Oldstone. 1986. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc. Natl. Acad. Sci. U. S. A. 83:7089-7093.
26. Yilmaz, A., M. Gisslen, S. Spudich, E. Lee, A. Jayewardene, F. Aweeka, and R. W. Price. 2009. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 4:e6877.